Phase III depression trial success for Alkermes
October 24, 2016Research and Development, Sales and Marketing ALKS 5461, Alkermes, major depressive disorder
Biopharma company Alkermes has announced the success of its ALKS 5461 treatment in a Phase III study for the treatment …
GSK applies for FDA approval for shingles vaccine
October 24, 2016Sales and Marketing GSK, GlaxoSmithKline, Vaccine, chickenpox, shingles
GlaxoSmithKlien, the UK’s biggest drugmaker, is seeking approval from the FDA for a shingles (herpes zoster) vaccine. The vaccine would …
Top Ten articles in the pharma industry this week
October 21, 2016Medical Communications biggest stories, news, week, weekly
This week has seen a few big collaboration and partnerships occur, whilst there have been some major movements within immunotherapy …
Merck KGaA and Pfizer team up with Debiopharm in lung cancer treatment
October 21, 2016Medical Communications Debiopharm, Merck KGaA, NSCLC, Pfizer, lung cancer
Debiopharm International, the Swiss-based global biopharmaceutical group of five companies, announced that it would be entering into an agreement with …
Gilead’s drug boosted by positive Phase II trials and aims to move forward
October 21, 2016Medical Communications Gilead, Gilead Sciences, clinical trials, fatty liver disease
Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The …
UK Government announces deep cuts to pharmacy funding
October 21, 2016Medical Communications Conservative, NHS, UK, government, pharmacy
The Department Health announced that it wanted to reduce the £2.8 billion a year funding for pharmacies by 7%, leading …
FDA advisory committee approves of Allergan’s night-time urination medicine
October 20, 2016Medical Communications Allergan, FDA, Night-time urination, sleep, urination
The FDA’s advisory committee ruled, in a 14-4 vote, that Allergan’s experimental nocturnal urination medication, SER120, in favour of the …
Eli Lilly gains accelerated approval from FDA for soft tissue sarcoma drug
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, US, soft tissue sarcoma
Eli Lilly received the positive news that their drug, Lartruvo, has been granted accelerated approval for use in conjunction with …
The Pharmafocus guide to the US presidential election 2016
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing US election, feature
The US presidential election is mere weeks away, and the pharmaceutical industry and drug pricing have occupied quite a large …
Novartis in collaboration deal worth potential $1.2 billion with Cerulean
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerulean, NDC, Novartis
Novartis has signed an agreement with Cerulean Pharma, worth a potential $1.2 billion depending on milestones met, to co-develop nanoparticle-drug …
Celgene’s Otezla approved by NICE for chronic plaque psoriasis
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, NICE, apremilast, otezla
NICE has given its approval to another indication for Celgene’s Otezla (apremilast), meaning NHS patients now have access to the …
MSD’s antiviral drug hits endpoint targets in Phase III trials
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AiCuris, MSD, Merck, bone marrow, letermovir, transplant
MSD, known as Merck in the US, released news of the successful meeting of its primary endpoints in its Phase …
Oxford Genetics boosts cell/gene therapy R&D with new facility
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Oxford Genetics, expansion
Oxford Genetics has moved its operations to the Medawar centre in the city, upscaling its infrastructure and staff to keep …
Specialist Clinical Trials Equipment Supplier Woodley Equipment Company Exhibiting at OCT Southern California
October 19, 2016Woodley Equipment is exhibiting at Outsourcing in Clinical Trials Southern California taking place on 26th and 27th October 2016 at …
Sun Pharma partners with ICGEB to develop dengue vaccine
October 19, 2016Research and Development Vaccine, dengue, icgeb, sun pharmaceutical
Indian drug firm Sun Pharma is set to join forces with the International Centre for Generic Engineering and Biotechnology (ICGEB) …
Lilly announces plan to expand global access to health care
October 19, 2016Research and Development Eli Lilly, Lilly 30x30, global health
Eli Lilly has announced a project, known as Lilly 30×30, which is a five-year, $90 million investment to improve access …
Roche’s immunotherapy cancer drug given FDA approval
October 19, 2016Research and Development Cancer, FDA, Genentech, Roche, immunotherapy, lung cancer
Coming off the back of earlier positive news this month, Roche has revealed that their drug, Tecentriq, has been given …
Recipharm to open largest Nordic GLP bioanalysis lab
October 19, 2016Manufacturing and Production, Research and Development Recipharm, Sweden, expansion
Contract development and manufacturing firm Recipharm has announced plans to invest five million Swedish Krona (SEK) in a new GLP-compliant …
FDA grants $23 million to boost research on rare diseases
October 19, 2016Research and Development Cancer, FDA, clinical trials, oncology
The FDA has continued their push to provide funding for experimental clinical trials into treatments of rare diseases. The FDA, …
Quark to set up “largest biotechnology fund in Canada” for $500m
October 18, 2016Manufacturing and Production, Research and Development Canada, Quark Venture, Vancouver, fund
Canadian venture capital firm Quark Venture is to partner up with China’s GF Securities to launch a “largest of its …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
